MAGL-IN-15, identified by its CAS number 2770967-08-1, is a selective inhibitor of the enzyme monoacylglycerol lipase (MAGL), which plays a crucial role in the endocannabinoid system by hydrolyzing monoacylglycerols. This compound is characterized by its ability to modulate cannabinoid signaling, potentially offering therapeutic benefits in various conditions, including pain, inflammation, and neurodegenerative diseases. MAGL-IN-15 exhibits high selectivity for MAGL over other lipases, making it a valuable tool in pharmacological research. Its chemical structure typically includes functional groups that enhance its binding affinity to the active site of the enzyme. The compound is often studied in preclinical models to assess its efficacy and safety profile. As with many research chemicals, detailed information regarding its pharmacokinetics, toxicity, and long-term effects is still under investigation, emphasizing the need for further studies to fully understand its potential applications in medicine.

MAGL-IN-15

2770967-08-1: MAGL-IN-15, identified by its CAS number 2770967-08-1, is a selective inhibitor of the enzyme monoacylglycerol lipase (MAGL), which plays a crucial role in the endocannabinoid system by hydrolyzing monoacylglycerols. This compound is characterized by its ability to modulate cannabinoid signaling, potentially offering therapeutic benefits in various conditions, including pain, inflammation, and neurodegenerative diseases. MAGL-IN-15 exhibits high selectivity for MAGL over other lipases, making it a valuable tool in pharmacological research. Its chemical structure typically includes functional groups that enhance its binding affinity to the active site of the enzyme. The compound is often studied in preclinical models to assess its efficacy and safety profile. As with many research chemicals, detailed information regarding its pharmacokinetics, toxicity, and long-term effects is still under investigation, emphasizing the need for further studies to fully understand its potential applications in medicine.

<p>MAGL-IN-15 (Compound 6), a MAGL inhibitor, holds potential for research into diseases and disorders associated with the regulation of endocannabinoid system signaling activities [1].</p>

CAS 2770967-08-1

MAGL-IN-15

MAGL-IN-15

Ref: TM-T86853